Rosenblum Silverman Sutton S F Inc Alnylam Pharmaceuticals, Inc. Transaction History
Rosenblum Silverman Sutton S F Inc
- $345 Million
- Q1 2024
A detailed history of Rosenblum Silverman Sutton S F Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Rosenblum Silverman Sutton S F Inc holds 35,470 shares of ALNY stock, worth $8.62 Million. This represents 1.54% of its overall portfolio holdings.
Number of Shares
35,470
Previous 37,053
4.27%
Holding current value
$8.62 Million
Previous $6.56 Million
19.23%
% of portfolio
1.54%
Previous 2.28%
Shares
15 transactions
Others Institutions Holding ALNY
# of Institutions
584Shares Held
104MCall Options Held
2.82MPut Options Held
1.75M-
Capital World Investors Los Angeles, CA12.8MShares$3.11 Billion0.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$2.91 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY9.03MShares$2.19 Billion0.03% of portfolio
-
Wellington Management Group LLP Boston, MA7.21MShares$1.75 Billion0.2% of portfolio
-
Baillie Gifford & CO6.62MShares$1.61 Billion0.78% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $29.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...